Bucladesine

Application
Dibutyryl cyclic adenosine monophosphate sodium is a derivative of cyclic adenosine monophosphate, which is used to treat cardiogenic shock and heart failure. In 1999, Dibutyryl cyclic adenosine monophosphate sodium ointment was developed to treat skin infection and skin ulcer.

Preparation of sodium dibutyryl cyclophosphate adenosine: In the flask containing cyclophosphate adenosine slowly add aqueous sodium hydroxide solution (3 mol/L) dropwise, the process controlled temperature, dropwise finished warming to room temperature, adjust the pH to 7 ~ 8 with HCl solution (20%), add anhydrous ethanol precipitation of white solid, filtration, drying to obtain a white solid sodium salt; the sodium salt and n-butyl anhydride under the protection of N2 warming to 140 ℃ reaction. TLC monitoring, the reaction is complete and then lowered to room temperature, slowly add methyl tert-butyl ether, the process of vigorous stirring, Chemicalbook to obtain a nearly white solid crude product. A mixture of methyl tert-butyl ether and acetone was resuspended to obtain a white powdered target product. Biological activityDibutyryl-cAMP(Bucladesine,dbcAMP) is a cell-permeable PKA activator that acts by mimicking endogenous cAMP.Dibutyryl-cAMP(Bucladesine) is also a phosphodiesterase(PDE) inhibitor.
In vitro studies:Dibutyryl-cAMP inhibits neuronal glucose uptake via PKA activation. In cultured rat hepatocytes, Dibutyryl-cAMP inhibits inducible nitric oxide synthase expression and NF-kappaB binding activity. dibutyrChemicalbookyl-cAMP also inhibits TNFalpha-induced rod cell apoptosis by inhibiting FADD upregulation.
In vivo studies:In a mouse model, Bucladesine (600nM/mouse,i.p.) reversed zinc chloride and lead acetate induced evasive memory retention impairment.